MBX Biosciences, Inc. (MBX) closed the last trading session at $15.86, gaining 54.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $60.29 indicates a 280.1% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $18.94. While the lowest estimate of $30.00 indicates an 89.2% increase from the current price level, the most optimisti ...

Biotech and Medical Tech Stocks to Watch - Big Moves Following Clinical Trial News October 8, 2025 - (Investorideas.com Newswire), a go-to investing platform covering biotech and medtech stocks releases an industry snapshot looking at recent clinical trial updates, featuring Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Recent clinical trial update news from Aethlon Medical, Inc. (Nasdaq: AE ...

In the past week or so, some public offerings of stock prompted big insider buying. ...

Summary of MBX Biosciences Conference Call Company Overview - **Company**: MBX Biosciences - **Industry**: Biopharmaceuticals, focusing on peptide drug design and development - **Key Products**: - Kaniparutide for hypoparathyroidism - MBX 1416, a GLP-1 antagonist for post-bariatric hypoglycemia - MBX 4291, a dual agonist for obesity Core Points and Arguments - **Kaniparutide**: - Positive Phase 2 results with a 79% responder rate at six months, up from 63% at 12 weeks [3] - Comparison with a once-daily injectable that has a 69% responder rate at six months [3] - 94% of trial participants chose to enroll in a two-year open-label extension study, indicating strong patient interest [4] - No treatment-related serious adverse events (SAEs) reported, highlighting safety and tolerability [4] - Positioned to establish a new standard of care in adults with hypoparathyroidism as it advances to Phase 3 registration study [4] - **MBX 1416**: - A potential first-in-class treatment for post-bariatric hypoglycemia (PBH) [4] - Currently in Phase 2a study, addressing a significant unmet need as there are no approved pharmacotherapies for PBH [19] - Mechanism of action involves GLP-1 antagonism, which is clinically validated [19] - Demonstrated a half-life of 90 hours, significantly longer than existing treatments [19] - **MBX 4291**: - An ultra-long-acting GLP-1/GIP co-agonist prodrug with potential for once-monthly dosing [5] - Aims for improved gastrointestinal tolerability and greater weight loss compared to current products [5] - Preclinical studies show superior pharmacokinetic profiles compared to tirzepatide, with a gradual controlled release [8] - Expected to enter Phase 1 study in high BMI adults, focusing on tolerability and weight loss [10] Financial Position - As of June 30, 2025, the company has approximately $412 million in cash, extending its operating runway into 2029 [5] - This financial strength supports the advancement of key milestones across its pipeline, including the Phase 3 study for Kaniparutide [5] Additional Insights - **Durability of Effect**: The prodrug design aims to improve patient adherence and reduce discontinuations, which is critical for obesity treatments [12] - **Market Landscape**: The company is aware of the competitive nature of the obesity field and is exploring various validated targets, including glucagon and amylin [16] - **Partnership Strategy**: The company plans to partner its obesity programs strategically, given the large registration studies and sales forces required [17] - **Regulatory Pathway**: The company is preparing for an end-of-Phase 2 meeting with the FDA to align on the Phase 3 registration study design for Kaniparutide [38] Conclusion MBX Biosciences is positioned as a transformative player in the biopharmaceutical industry, particularly in the areas of hypoparathyroidism and obesity, with promising clinical data and a strong financial foundation to support its innovative pipeline. The focus on patient adherence and tolerability, along with strategic partnerships, will be crucial for its success in a competitive market.

CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, MD, Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum on September 30. Stifel 2025 Virtual Cardiome ...

Group 1: Stitch Fix, Inc. - Stitch Fix reported a quarterly loss of $0.07 per share, which was better than the consensus estimate of a loss of $0.10 per share [1] - The company's quarterly revenue was $311.22 million, exceeding the Street estimate of $305.83 million [1] - Despite the positive revenue results, Stitch Fix shares dipped 7.6% to $5.21 in pre-market trading [1] Group 2: Other Stocks - Transocean Ltd. saw a decline of 14.7% to $3.10 following the announcement of an upsized public offering of shares [4] - Nanobiotix S.A. fell 9.8% to $14.83 after previously gaining over 15%, related to new results from a Phase 1 study [4] - MBX Biosciences, Inc. dropped 5.5% to $19.00 due to the pricing of an upsized public offering [4] - Other companies such as Galectin Therapeutics Inc., Amprius Technologies, Inc., and Canaan Inc. also experienced declines in pre-market trading [4]

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.Shares of Stitch Fix, Inc. (NASDAQ: SFIX) dipped 7.6% to $5.21 in pre-market trading following the release of fourth-quarter results.Stitch Fix reported quarterly losses of seven cents per share, which beat the consensus estimate for losses of 10 cents. Quarterly revenue came in at $311.22 million, which beat the Street estimate of $305.83 million.Stitch Fix shares fell 4.6% to $5.38 in pre-market trading.Here a ...

Meetings with Growth-Oriented Investors, September 26 to 28, 2025MISSISSAUGA, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Muskoka Capital Event, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, Ontario, September 26 to 28, 2025. Microbix’s CEO, Cameron Groome, and COO, Ken Hughes ...

Core Insights - MBX Biosciences announced positive top-line results from its Phase II clinical trial of once-weekly canvuparatide for patients with hypoparathyroidism [2] Group 1: Clinical Trial Results - The Phase II trial demonstrated promising outcomes for canvuparatide in treating hypoparathyroidism [2] - Six-month results from the ongoing open-label extension study were also reported [2] Group 2: Company Leadership - The conference call featured key executives from MBX, including CEO Kent Hawryluk, CMO Dr. Sam Azoulay, and CFO Rick Bartram [4]

Company Overview - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel precision peptide therapies for endocrine and metabolic disorders [5] - The company utilizes its proprietary PEP™ platform to advance a pipeline of candidates targeting significant unmet medical needs with large market opportunities [5] Public Offering Details - MBX Biosciences announced the pricing of its upsized public offering of 11,108,055 shares at a price of $18.00 per share, expecting gross proceeds of approximately $199.9 million before deductions [1] - The offering includes a 30-day option for underwriters to purchase an additional 1,666,208 shares at the public offering price [1] - The offering is expected to close on September 26, 2025, pending customary closing conditions [1] Underwriters - J.P. Morgan, Jefferies, TD Cowen, and Guggenheim Securities are acting as joint book-running managers for the offering [2] - Citizens Capital Markets and Oppenheimer & Co. are serving as co-lead managers [2] Regulatory Compliance - A registration statement for the offering was filed with the Securities and Exchange Commission and declared effective on September 24, 2025 [3] - The offering is being conducted solely through a prospectus [3]